March 2020 issue
March 31, 2020 | Cirtec Medical Corp., the Brooklyn Park, MN manufacturer of neuromodulation system components and subassemblies, announced that it has acquired intellectual property and certain assets from Nuvectra Corp., the Greatbatch spinoff that recently filed for bankruptcy protection. Cirtec will leverage this technology to support customers’ development of neuromodulation products, providing an FDA-approved platform with a complete design history file to leverage for a variety of therapeutic applications.
The Nuvectra assets include all owned intellectual property associated with the spinal cord stimulation, deep brain stimulation, and sacral nerve stimulation platforms, which are renowned for their patient-centric ease-of-use, and discrete and portable design, together with a versatile and expandable platform that helps sustain therapy for the long-term benefit of patients.
Brian Highley, Cirtec CEO commented, “Cirtec is committed to serving as the leading end-to-end outsource partner in the neuromodulation market. This acquisition is part of our broader strategy to accelerate our customers’ time to market, minimize development spend, and commercialize innovative solutions for therapy delivery. Our portfolio of off-the-shelf components; a robust engineering team; and significant manufacturing capacity and expertise make us the leading partner to innovators in the market.”
The acquisition complements Cirtec’s Solace neurostimulation R&D platform, bolstering the company’s offering across the full range of devices and accessories offered, including an IPG, trial pulse generator, patient remote, clinician programmer and IPG charger, plus a portfolio of percutaneous leads, paddle leads, extensions, and locking anchors.
